NDAORALTABLETPriority Review
Approved
Jul 2015
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TECHNIVIE is a fixed-dose combination oral tablet containing ombitasvir, paritaprevir, and ritonavir, approved by the FDA in July 2015 for the treatment of chronic hepatitis C virus (HCV) infection. It represents a direct-acting antiviral (DAA) regimen designed to inhibit HCV nonstructural proteins NS5A and NS3/4A protease. This small molecule combination targets patients with HCV genotype 4 infection, particularly those without cirrhosis or with compensated cirrhosis.
Peak5.9 years to LOE
Product is in peak commercial stage with stable market presence; brand team likely maintains established size focused on market retention and patient support.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TECHNIVIE positions you in a mature, stable commercial franchise within virology/infectious disease but with declining growth opportunities as generics approach in 2032. Roles focus on defending market share, optimizing patient access, and preparing transition strategies rather than new indication expansion or significant revenue growth.
Brand ManagerMedical Science Liaison (MSL)
Worked on TECHNIVIE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.